GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » OraSure Technologies Inc (NAS:OSUR) » Definitions » GF Value

OraSure Technologies (OraSure Technologies) GF Value : $5.71 (As of Apr. 28, 2024)


View and export this data going back to 1992. Start your Free Trial

What is OraSure Technologies GF Value?

The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on three factors:

  1. Historical multiples (PE Ratio, PS Ratio, PB Ratio and Price-to-Free-Cash-Flow) that the stock has traded at.
  2. GuruFocus adjustment factor based on the company’s past returns and growth.
  3. Future estimates of the business performance.

We believe the GF Value Line is the fair value that the stock should be traded at. The stock price will most likely fluctuate around the GF Value Line. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher.

Please note, "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

As of today (2024-04-28), OraSure Technologies's share price is $5.32. OraSure Technologies's GF Value is $5.71. Therefore, OraSure Technologies's Price-to-GF-Value for today is 0.93.

Based on the relationship between the current stock price and the GF Value, GuruFocus believes OraSure Technologies is Fairly Valued.


OraSure Technologies  (NAS:OSUR) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:

Posssible Evaluations All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)Predictable Companies that possibly be Value Traps
Significantly OvervaluedPredictable Companies which are Significantly Overvalued
Modestly OvervaluedPredictable Companies which are Modestly Overvalued
Fairly ValuedPredictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) There is only a sufficient margin of safety when the stock is undervalued.

OraSure Technologies's Price-to-GF-Value for today is calculated as

Price-to-GF-Value=Share Price/GF Value
=5.32/5.71
=0.93

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


OraSure Technologies GF Value Related Terms

Thank you for viewing the detailed overview of OraSure Technologies's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.


OraSure Technologies (OraSure Technologies) Business Description

Traded in Other Exchanges
Address
220 East First Street, Bethlehem, PA, USA, 18015
OraSure Technologies is a medical devices company that develops, manufactures, and distributes oral fluid diagnostic and collection devices. Its reportable segments are diagnostics and molecular solutions. The diagnostics segment produces rapid oral diagnostic tests and specimen collection devices for infectious diseases such as HIV and HCV. The molecular solutions segment specializes in kits used to collect, stabilize, and transport genetic material samples for molecular testing of both hereditary diseases and infectious diseases, such as COVID-19. The company gets most of its sales from the molecular solutions business, derived mainly from customers in the United States.
Executives
Kathleen Gallagher Weber officer: Chief Product Officer 220 EAST FIRST STREET, BETHLEHEM PA 18017
Michele Marie Miller officer: VP, Finance and Controller 220 EAST FIRST STREET, BETHLEHEM PA 18017
Robert W. Mcmahon director 250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Kenneth J Mcgrath officer: Chief Financial Officer C/O ORASURE TECHNOLOGIES, INC., 220 E. FIRST STREET, BETHLEHEM PA 18015
Ronny B Lancaster director ORASURE TECHNOLOGIES INC, 220 EAST FIRST STREET, BETHLEHEM PA 18015
Mara G. Aspinall director 7381 NORTH MOON SPIRIT LANE, TUCSON AZ 85718
Nancy J Gagliano director 33 GRANITE WAY, GRANTHAM NH 03753
Michael Celano director 220 EAST FIRST STREET, BETHLEHEM PA 18015
Manner Carrie Eglinton director, officer: President & CEO C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
Scott Gleason officer: Interim CFO/SVP IR 1809 SOUTH 2500 EAST, SALT LAKE CITY UT 84108
Eamonn P Hobbs director C/O DELCATH SYSTEMS, INC., 600 FIFTH AVENUE, NEW YORK NY 10020
Anne Clem Whitaker director 109 BRIERY BRANCH COURT, MORRISVILLE NC 27560
James A Datin director 21 ESTATES DRIVE, DOYLESTOWN PA 18901
Lelio Marmora director 64 RUE DE VESENEX, DIVONNE LES BAINS I0 01220
Lisa Nibauer officer: President of Diagnostics 1 CRESENT PLACE, SHORT HILLS NJ 07078